

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandria, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/536,533	11/29/2005	Ganga Prasad Rai	4544-051675	7482
28289 THE WERR I	7590 AW FIRM, P.C.	EXAMINER		
700 KOPPERS BUILDING 436 SEVENTH AVENUE			HINES, JANA A	
PITTSBURGE			ART UNIT	PAPER NUMBER
			1645	
			NOTIFICATION DATE	DELIVERY MODE
			05/04/2011	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patents@webblaw.com

## **Advisory Action** Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/536,533	RAI ET AL.		
Examiner	Art Unit		
JA'NA HINES	1645		

	JA'NA HINES	1645	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress
THE REPLY FILED 05 April 2011 FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR AL	LOWANCE.	
<ol> <li>X The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:</li> </ol>	replies: (1) an amendment, affidavil eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires 4 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire is	dvisory Action, or (2) the date set forth i	in the final rejection, whi date of the final rejection	chever is later. In
Examiner Note: If box 1 is checked, check either box (a) or ( MONTHS OF THE FINAL REJECTION, See MPEP 706.07(		FIRST REPLY WAS FII	ED WITHIN TWO
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filled is the date for purpose of determining the period at under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	on which the petition under 37 CFR 1.1: ension and the corresponding amount of hortened statutory period for reply origing than three months after the mailing dat	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with</li> </ol>	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
AMENDMENTS			
<ol> <li>The proposed amendment(s) filed after a final rejection, to (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE belowed).</li> </ol>	sideration and/or search (see NOT		cause
(c) They are not deemed to place the application in bett appeal; and/or		ducing or simplifying the	ne issues for
(d) They present additional claims without canceling a c NOTE:	corresponding number of finally reje	ected claims.	
4. The amendments are not in compliance with 37 CFR 1.12	21 See attached Notice of Non-Co.	mnliant Amendment (	PTOL -324)
5. Applicant's reply has overcome the following rejection(s):		inplicate / international (	TOE OE+).
Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	it canceling the
7.  For purposes of appeal, the proposed amendment(s): a) \( \bigcirc \) how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		be entered and an ex	planation of
Claim(s) allowed: None.			
Claim(s) objected to: None.			
Claim(s) rejected: <u>23-27</u> . Claim(s) withdrawn from consideration: <u>28</u> .			
AFFIDAVIT OR OTHER EVIDENCE			
The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	of the status of the claims after er	ntry is below or attach	ed.
11. The request for reconsideration has been considered but	does NOT place the application in	condition for allowan	ce because:
12.  Note the attached Information Disclosure Statement(s). (13.  Other:	PTO/SB/08) Paper No(s).		
	/Mark Navarro/		
	Primary Examiner, Art U	nit 1645	

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

The proposed after final amendment will not be entered. The proposed amendment filed after final rejection raises new issues that would require further consideration and/or search. Moreover, the proposed amendment is not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal.

Therefore claims 24-25 rejected under 103(a) as being Nilsson et al., in view of Sukosol et al., is maintained for reasons already of record in order to have an agglutination reagent for a more sensitive and specific detection.

Claims 23-24 and 26-27 are rejected under 103(a) as being unpatentable over Nilsson et al., Sukosol et al., Salzman et al., and Fruitstone et al., for the reasons already of record. The rejection was on the groundst vuold have been prima face obtax at the time of applicants' invention to apply the antibody specific to the flagellin gene of Salmonella typh is a taught by Sukosol et al., the preparation of the of the purified protein as taught by Salzman et al., and the storage buffers as taught by Fruitstone et al., to the metarion of agglutination reagents as taught by Alisson et al., in order to provide advantageously achieve for agglutination reagent used for diagnosis which overcomes disadvantages associated with agglutination test while providing highly selective and sensitive typhoid detection.